Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : WHO backs Regeneron COVID-19 drug cocktail as UN body calls for equal access

09/23/2021 | 07:01pm EDT

Sept 24 (Reuters) - A World Health Organization (WHO) panel on Friday recommended the use of Regeneron and Roche's COVID-19 antibody cocktail for patients at high risk of hospitalisations and those severely ill with no natural antibodies.

The treatment has been granted U.S. emergency use authorisation, having gained attention when used to treat former President Donald Trump's COVID-19 illness last year. Europe is reviewing the therapy, while Britain approved it last month.

While acknowledging costs associated with the treatment, the WHO panel said that given the recorded benefits of the therapy, "the recommendations should provide a stimulus to engage all possible mechanisms to improve global access to the intervention and associated testing."

In a separate statement, the WHO called on Regeneron to lower prices and distribute the treatment equitably worldwide, especially in low- and middle-income countries. The agency also urged the firms to transfer tech to help make biosimilars.

The treatment, called Ronapreve, or REGEN-COV in the United States, has been a big earner for Regeneron, logging in U.S. sales of $2.59 billion in the second quarter.

Regeneron is going to supply 1.4 million additional doses of REGEN-COV https://www.reuters.com/world/us/us-buy-14-mln-additional-doses-regenerons-covid-19-therapy-2021-09-14 to the U.S. government by Jan. 31 at a cost of $2,100 per dose.

French medical charity Medecins Sans Frontieres (MSF) echoed the UN agency's comments, demanding that affordable and sustainable access to life-saving drugs during the pandemic must be ensured.

The WHO guidelines, published in the British Medical Journal (BMJ), were based on data from a large British study and three other trials that have not yet been peer reviewed.

In June, Britain's RECOVERY trial https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-covid-19-therapy-cuts-deaths-among-hospitalised-patients-who-lack-2021-06-16 found the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.

The treatment, a combination of casirivimab and imdevimab, is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Krishna Chandra Eluri)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS 2.40% 590 Delayed Quote.19.27%
ROCHE HOLDING AG 0.20% 357.95 Delayed Quote.15.61%
All news about REGENERON PHARMACEUTICALS
09:53aSVB Leerink Adjusts Regeneron Pharmaceuticals' Price Target to $798 from $785, Keeps Ou..
MT
10/25ZAI LAB : Says First Patient Treated in China Portion of Global Study of Odronextamab for ..
MT
10/25REGENERON PHARMACEUTICALS : Second dupixent (dupilumab) phase 3 eosinophilic esophagitis t..
AQ
10/25SANOFI : Regeneron's Second Late-Stage Inflammatory Disease Trial Meets Primary Endpoints
MT
10/25SANOFI : Regeneron's Dupixent Improves Swallowing in Late-Stage Study
MT
10/25REGENERON PHARMACEUTICALS : Second Dupixent« (dupilumab) Phase 3 Eosinophilic Esophagitis ..
PR
10/22SANOFI : Regeneron's Dupixent Meets Primary, Key Secondary Endpoints in Phase 3 Trial in P..
MT
10/22REGENERON, SANOFI : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial
DJ
10/22SANOFI : Regeneron's Dupixent Cuts Itch in Late-Stage Skin Disease Study
MT
10/21REGENERON PHARMACEUTICALS : Fda expands approval of dupixent (dupilumab) to include childr..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 14 402 M - -
Net income 2021 7 227 M - -
Net Debt 2021 - - -
P/E ratio 2021 8,71x
Yield 2021 -
Capitalization 59 906 M 59 906 M -
Capi. / Sales 2021 4,16x
Capi. / Sales 2022 4,91x
Nbr of Employees 9 635
Free-Float 82,0%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 576,20 $
Average target price 682,14 $
Spread / Average Target 18,4%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS19.27%59 906
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
VERTEX PHARMACEUTICALS-21.73%47 992
BEIGENE, LTD.49.95%36 160